We are live on ! Find out more
HP

HealthInvest Partners Portfolio holdings

AUM $372M
1-Year Est. Return 59.89%
This Fund
S&P 500
This Quarter Est. Return
+18.37%
1 Year Est. Return
+59.89%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$313M
AUM Growth
+$286M
Cap. Flow
+$41.5M
Cap. Flow %
13.24%
Top 10 Hldgs %
52.99%
Holding
46
New
8
Increased
17
Reduced
12
Closed
7

Top Buys

Rank Stock Value
1
CVS icon
CVS Health
CVS
+$8.4M
2
IONS icon
Ionis Pharmaceuticals
IONS
+$6.96M
3
INCY icon
Incyte
INCY
+$6.86M
4
INSM icon
Insmed
INSM
+$5.09M
5
ABBV icon
AbbVie
ABBV
+$3.66M

Top Sells

Rank Stock Value
1
LLY icon
Eli Lilly
LLY
+$5.84M
2
GILD icon
Gilead Sciences
GILD
+$3.33M
3
BBIO icon
BridgeBio Pharma
BBIO
+$2.19M
4
KRYS icon
Krystal Biotech
KRYS
+$1.75M
5
COR icon
Cencora
COR
+$1.65M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CAH icon
26
Cardinal Health
CAH
$55.9B
$4.82M 1.54%
23,470
-6,827
-23% -$1.28M
ABVX
27
Abivax
ABVX
$11.1B
$4.26M 1.36%
+31,590
New +$3.45M
CELC icon
28
Celcuity
CELC
$4.3B
$4.17M 1.33%
41,831
+4,674
+13% +$384K
IRON icon
29
Disc Medicine
IRON
$3.12B
$3.81M 1.22%
47,967
+2,277
+5% +$192K
IDYA icon
30
IDEAYA Biosciences
IDYA
$3.55B
$3.37M 1.07%
+97,438
New +$3.11M
UNH icon
31
UnitedHealth
UNH
$361B
$3.19M 1.02%
14,636
+909
+7% +$308K
CMPX icon
32
Compass Therapeutics
CMPX
$396M
$3.14M 1%
+584,332
New +$2.7M
SLNO
33
DELISTED
Soleno Therapeutics
SLNO
$2.9M 0.93%
62,735
+2,579
+4% +$141K
ACLX
34
DELISTED
Arcellx
ACLX
$2.72M 0.87%
41,717
+15,985
+62% +$1.28M
DXCM icon
35
DexCom
DXCM
$33.8B
$2.64M 0.84%
39,722
-11,150
-22% -$721K
AUTL
36
Autolus Therapeutics
AUTL
$620M
$2.33M 0.74%
1,169,634
– –
BCAX
37
Bicara Therapeutics
BCAX
$1.56B
$1.87M 0.6%
111,363
-92,392
-45% -$1.58M
CRBP icon
38
Corbus Pharmaceuticals
CRBP
$184M
$873K 0.28%
107,255
-68,327
-39% -$843K
PYXS icon
39
Pyxis Oncology
PYXS
$179M
$710K 0.23%
+617,245
New +$2.18M
EW icon
40
Edwards Lifesciences
EW
$54B
– –
-65,659
Closed -$542K
HRMY icon
41
Harmony Biosciences
HRMY
$2.3B
– –
-92,074
Closed -$269K
JANX icon
42
Janux Therapeutics
JANX
$1.01B
– –
-49,820
Closed -$129K
MREO
43
Mereo BioPharma
MREO
$48.8M
– –
-764,901
Closed -$167K
MRUS
44
DELISTED
Merus
MRUS
– –
-47,999
Closed -$480K
RNAM
45
DELISTED
Avidity Biosciences
RNAM
– –
-51,978
Closed -$240K
SMMT icon
46
Summit Therapeutics
SMMT
$12.1B
– –
-92,737
Closed -$203K
1
2

Similar funds

KP
Kiltearn Partners Edinburgh, United Kingdom $372M AUM 18.16% 1-Year Est. Return
TCM
Thomist Capital Management Houston, Texas $371M AUM 77.62% 1-Year Est. Return
SAAM
Solus Alternative Asset Management Summit, New Jersey $372M AUM 45.33% 1-Year Est. Return
PC
Promethos Capital Boston, Massachusetts $372M AUM 23.19% 1-Year Est. Return
GIP
Gavilan Investment Partners Burlingame, California $372M AUM 6.04% 1-Year Est. Return
PC
Prevatt Capital Nassau, Bahamas $371M AUM 9.39% 1-Year Est. Return
DPCM
Doma Perpetual Capital Management Miami, Florida $372M AUM 14.96% 1-Year Est. Return
OCMH
Oxbow Capital Management (HK) Hong Kong $371M AUM 383.45% 1-Year Est. Return

HealthInvest Partners's Q4 2025 Portfolio in Review

As of Q4 2025, HealthInvest Partners held 46 positions worth $313M, up 1,062% from $27M the previous quarter. Its ten largest holdings account for 53% of the portfolio.

HealthInvest Partners deployed $41.5M of net new capital in Q4 2025, opening 8 new positions and adding to 17 existing holdings. Its largest new stake was CVS Health: 106,518 shares worth $8.45M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Eli Lilly, an estimated $5.84M trimmed.

  • HealthInvest Partners's largest Q4 2025 buy was CVS Health: 106,518 shares worth $8.45M.
  • HealthInvest Partners added most to AbbVie in Q4 2025, an estimated $3.66M increase.
  • HealthInvest Partners's biggest Q4 2025 reduction was Eli Lilly, cutting an estimated $5.84M.
  • HealthInvest Partners fully exited Edwards Lifesciences in Q4 2025, selling an estimated $542K.
  • HealthInvest Partners's ten largest holdings make up 53% of its $313M portfolio in Q4 2025.
  • HealthInvest Partners opened 8 new positions and closed 7 in Q4 2025.
  • HealthInvest Partners's portfolio value rose 1,062% quarter-over-quarter to $313M.

Based on HealthInvest Partners's 13F filing for Q4 2025, filed 6 Feb 2026.